Trial Profile
Phase III Clinical Study of JTE-052 Ointment - Randomized Controlled and Long-Term Extension Study of JTE-052 Ointment in Japanese Pediatric Patients with Atopic Dermatitis -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Delgocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Japan Tobacco; Torii Pharmaceutical
- 09 Jun 2021 Status changed from recruiting to completed.
- 09 Jun 2021 Results assessing the efficacy and safety of delgocitinib ointment in pediatric patients with Atopic dermatitis published in the Journal of the American Academy of Dermatology
- 25 Apr 2021 Results presented at the American Academy of Dermatology Virtual Meeting Experience 2021